Custirsen

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 was tested with docetaxel (chemotherapy) in a randomized phase II trial. The results of the trial reported better overall survival in the combination arm (median, 23.8 and 16.9 months, respectively).28 Two additional phase III trials are ongoing to confirm these results in combination with chemotherapy: [...]

Dr. Mark Scholz Discusses Treatment Issues For Advanced Prostate Cancer

At the recent 2011 Prostate Cancer Research Institute Dr. Mark Scholz discussed care issues for men with advanced metastatic prostate cancer. In his presentation he stressed the importance of closely monitoring each man’s individual, on-going response to treatment to determine its effectiveness. He made a case that without close monitoring; treatment decisions would lag behind disease state. Dr. Scholz said that he believes that it is important to change treatments after 60-90 days if there hasn’t been an adequate response, or if there are excessive side effects. He suggested the following monitoring benchmarks: • Changes in pain • Checking PSA, [...]

Malecare’s Advanced Prostate Cancer Program

Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against prostate cancer.  Advanced and Recurrent Prostate Cancer kills 30,000 Americans and countless thousands more in other countries. We have been concerned that there is not enough attention being paid to advanced and recurrent prostate cancer, the cancer that actually kills. To increase the emphases needed on advanced and recurrent prostate cancer, we’re enhancing our Advanced Prostate Cancer Program with our new set of Prostate Cancer Kits, each kit having a number of different components. Our first and just released kit is focused on helping men and their loved ones who have already survived their initial prostate cancer diagnosis and are now dealing with recurrent disease. The recurrent prostate cancer kit includes a just published, detailed, easy to read guide on how to understand and navigate living with recurrent prostate cancer. This guide is a must read for anyone with recurrent prostate cancer and anyone who supports a man with recurrent prostate cancer. Malecare will also be rolling out a new series of telephone and on-line support groups for men with advanced prostate cancer, their families and caregivers. The kit will also include additional teleconferences with experts in the field, more questions and answers from our doctors as well as our new interactive forum on prostate cancer. We have also initiated a training program open to all support groups leaders from any other organization that is helping men with prostate cancer. Our goal is to help anyone interested in improving the life of men dealing with prostate cancer. We’re ready and willing to share our unique advanced prostate cancer support group expertise, so that you can better help the men in your groups. So, to start, visit http://malecare.org and click the “advanced prostate cancer button.” You will be asked to register so that we can send you document updates as they are produced. Please let me know what you think about our programs as well as any suggestions of additional services we could provide. JOEL T. Nowak, M.A., M.S.W. […]

On the Horizon- Custirsen for Men with Advanced Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate cancer.  The median overall survival for men who were treated with custirsen plus first-line docetaxel plus prednisone was 23.8 months compared to 16.9 months for men treated with docetaxelplus prednisone alone, the current standard of care.  This is almost a seven month increase in life [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー